MA34545B1 - Co-cristaux et sels d'inhibiteurs de ccr3 - Google Patents

Co-cristaux et sels d'inhibiteurs de ccr3

Info

Publication number
MA34545B1
MA34545B1 MA35770A MA35770A MA34545B1 MA 34545 B1 MA34545 B1 MA 34545B1 MA 35770 A MA35770 A MA 35770A MA 35770 A MA35770 A MA 35770A MA 34545 B1 MA34545 B1 MA 34545B1
Authority
MA
Morocco
Prior art keywords
crystals
salts
ccr3 inhibitors
ccr3
inhibitors
Prior art date
Application number
MA35770A
Other languages
English (en)
Inventor
Markus Frank
Hans Haeberle
Manuel Henry
Thorsten Pachur
Marco Santagostino
Uwe Stertz
Thomas Trebing
Ulrike Werthmann
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA34545B1 publication Critical patent/MA34545B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne des co-cristaux et des sels d'inhibiteurs de CCR3 de formule (1), des compositions pharmaceutiques les contenant et des procédés d'utilisation de ceux-ci en tant qu'agents pour le traitement et/ou la prévention de maladies associées au récepteur CCR3.
MA35770A 2010-10-07 2011-10-06 Co-cristaux et sels d'inhibiteurs de ccr3 MA34545B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10186901 2010-10-07
PCT/EP2011/067437 WO2012045803A1 (fr) 2010-10-07 2011-10-06 Co-cristaux et sels d'inhibiteurs de ccr3

Publications (1)

Publication Number Publication Date
MA34545B1 true MA34545B1 (fr) 2013-09-02

Family

ID=44741339

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35770A MA34545B1 (fr) 2010-10-07 2011-10-06 Co-cristaux et sels d'inhibiteurs de ccr3

Country Status (37)

Country Link
US (3) US8742115B2 (fr)
EP (1) EP2625174B1 (fr)
JP (1) JP5794713B2 (fr)
KR (3) KR102239690B1 (fr)
CN (1) CN103140486B (fr)
AP (1) AP3268A (fr)
AR (1) AR083353A1 (fr)
AU (1) AU2011311530B2 (fr)
BR (2) BR112013008211B1 (fr)
CA (1) CA2807255C (fr)
CL (1) CL2013000488A1 (fr)
CO (1) CO6710910A2 (fr)
CY (1) CY1116168T1 (fr)
DK (1) DK2625174T3 (fr)
EA (1) EA029097B1 (fr)
EC (1) ECSP13012600A (fr)
ES (1) ES2535264T3 (fr)
GE (1) GEP20166488B (fr)
HR (1) HRP20150419T1 (fr)
HU (1) HUE024540T2 (fr)
IL (1) IL224269A (fr)
MA (1) MA34545B1 (fr)
ME (1) ME02040B (fr)
MX (1) MX2013003785A (fr)
MY (1) MY167898A (fr)
NZ (1) NZ605827A (fr)
PE (1) PE20140188A1 (fr)
PH (1) PH12013500644A1 (fr)
PL (1) PL2625174T3 (fr)
PT (1) PT2625174E (fr)
RS (1) RS53858B1 (fr)
SG (1) SG188949A1 (fr)
SI (1) SI2625174T1 (fr)
TW (1) TWI546294B (fr)
UA (1) UA109290C2 (fr)
UY (1) UY33655A (fr)
WO (1) WO2012045803A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
AR090566A1 (es) 2012-04-02 2014-11-19 Boehringer Ingelheim Int Proceso para la produccion de inhibidores de crr
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) * 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
US11382907B2 (en) 2017-04-05 2022-07-12 Alkahest, Inc. Methods and compositions for treating aging-associated impairments using CCR3-inhibitors
US20200054622A1 (en) * 2017-04-05 2020-02-20 Alkahest, Inc. Methods and Compositions for Treating Aging-Associated Impairments Using CCR3-Inhibitors
EA201992356A1 (ru) * 2017-04-05 2020-03-23 Алкахест Инк. Способ и композиция для лечения заболевания, связанного с сетчаткой глаза, с использованием ингибитора ccr3
CA3076017A1 (fr) * 2017-10-13 2019-04-18 Alkahest, Inc. Methodes et compositions pour pour traiter un prurit, un xerosis et une maladie associee a l'aide d'inhibiteurs de ccr3
US11426399B2 (en) 2018-05-15 2022-08-30 Alkahest, Inc. Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase
EP3856195A4 (fr) * 2018-09-26 2022-06-22 Alkahest, Inc. Procédés et compositions pour traiter des troubles liés au vieillissement au moyen d'inhibiteurs de ccr3
US12692301B2 (en) 2020-06-11 2026-07-28 Alkahest Inc. Methods of improving retina-associated disease outcome using CCR3-inhibitors
CA3221177A1 (fr) 2021-11-01 2023-05-04 Meghan Kerrisk Campbell Modulateurs de benzodioxane de leucotriene a4 hydrolase (lta4h) pour la prevention et le traitement de maladies liees au vieillissement

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7907121L (sv) 1979-08-27 1981-02-28 Astra Laekemedel Ab Ftalimidinderivat
JP2807577B2 (ja) 1990-06-15 1998-10-08 エーザイ株式会社 環状アミド誘導体
WO1999037619A1 (fr) 1998-01-21 1999-07-29 Millennium Pharmaceuticals, Inc. Antagonistes du recepteur de la chemokine et procedes d'emploi desdits antagonistes
EP1052992A1 (fr) 1998-02-02 2000-11-22 Merck & Co., Inc. Amines cycliques utilisees en tant que modulateurs de l'activite du recepteur de chemokine
US6140349A (en) 1998-02-02 2000-10-31 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
WO2003066593A2 (fr) 2001-11-29 2003-08-14 Schering Corporation Preparation de sels pharmaceutiques
JP5069905B2 (ja) * 2003-01-21 2012-11-07 アプテュイト （ウエスト ラファイエット）、エルエルシー 新規な共結晶化
EP1680408A2 (fr) 2003-10-24 2006-07-19 F. Hoffmann-La Roche Ag Antagonistes du recepteur ccr3
EP1725235B1 (fr) 2004-02-05 2009-04-15 Schering Corporation Derives de piperidine utiles comme antagonistes de ccr3
EP1765379A4 (fr) 2004-06-17 2009-05-27 Transform Pharmaceuticals Inc Compositions pharmaceutiques de co-cristal et methodes d'utilisation associees
JP2006137718A (ja) 2004-11-12 2006-06-01 Astellas Pharma Inc インドール若しくはインダゾール誘導体
WO2006083390A2 (fr) 2004-12-07 2006-08-10 Children's Hospital Medical Center Eotaxine-3 dans l'oesophagite eosinophile
DOP2006000051A (es) 2005-02-24 2006-08-31 Lilly Co Eli Inhibidores de vegf-r2 y métodos
JP3701964B1 (ja) * 2005-03-08 2005-10-05 アステラス製薬株式会社 キヌクリジン誘導体の新規な塩
CA2647448A1 (fr) * 2006-04-12 2007-10-18 Pfizer Limited Composes chimiques
KR101176697B1 (ko) * 2006-04-20 2012-08-23 에프. 호프만-라 로슈 아게 케모카인 수용체의 다이아제판 유도체 조절자
GB0701992D0 (en) 2007-02-02 2007-03-14 7Tm Pharma As Grehlin Receptor Modulators
US8008092B2 (en) 2007-10-09 2011-08-30 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
TW201000446A (en) 2008-05-30 2010-01-01 Astrazeneca Ab New compounds useful in pain therapy
US8278302B2 (en) * 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) * 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
AR090566A1 (es) 2012-04-02 2014-11-19 Boehringer Ingelheim Int Proceso para la produccion de inhibidores de crr
US20130261153A1 (en) 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists

Also Published As

Publication number Publication date
CN103140486A (zh) 2013-06-05
IL224269A (en) 2017-08-31
ME02040B (me) 2015-05-20
EA201300436A8 (ru) 2018-01-31
KR102163874B1 (ko) 2020-10-12
KR20180005717A (ko) 2018-01-16
CN103140486B (zh) 2016-08-03
WO2012045803A1 (fr) 2012-04-12
CA2807255C (fr) 2018-11-13
BR112013008211A8 (pt) 2017-10-10
US9233950B2 (en) 2016-01-12
EP2625174B1 (fr) 2015-01-21
BR122021010665B1 (pt) 2022-03-15
AR083353A1 (es) 2013-02-21
MY167898A (en) 2018-09-26
SI2625174T1 (sl) 2015-03-31
BR112013008211A2 (pt) 2016-06-21
US8742115B2 (en) 2014-06-03
ES2535264T3 (es) 2015-05-07
UY33655A (es) 2012-04-30
CY1116168T1 (el) 2017-02-08
CL2013000488A1 (es) 2013-07-05
HUE024540T2 (hu) 2016-01-28
KR20130118313A (ko) 2013-10-29
US20140135307A1 (en) 2014-05-15
MX2013003785A (es) 2013-06-05
KR20190104645A (ko) 2019-09-10
PL2625174T3 (pl) 2015-06-30
KR101844215B1 (ko) 2018-04-03
EP2625174A1 (fr) 2013-08-14
RS53858B1 (sr) 2015-08-31
ECSP13012600A (es) 2013-07-31
EA201300436A1 (ru) 2013-08-30
PE20140188A1 (es) 2014-02-26
SG188949A1 (en) 2013-05-31
CO6710910A2 (es) 2013-07-15
PH12013500644A1 (en) 2013-05-20
HRP20150419T1 (hr) 2015-05-22
EA029097B1 (ru) 2018-02-28
DK2625174T3 (da) 2015-02-02
AP2013006679A0 (en) 2013-01-31
AU2011311530A1 (en) 2013-01-31
GEP20166488B (en) 2016-06-10
BR112013008211B1 (pt) 2021-08-24
JP2013542207A (ja) 2013-11-21
PT2625174E (pt) 2015-03-09
AU2011311530B2 (en) 2015-04-09
UA109290C2 (uk) 2015-08-10
KR102239690B1 (ko) 2021-04-13
US20120264729A1 (en) 2012-10-18
NZ605827A (en) 2015-09-25
TW201305134A (zh) 2013-02-01
AP3268A (en) 2015-05-31
US20150105371A1 (en) 2015-04-16
CA2807255A1 (fr) 2012-04-12
JP5794713B2 (ja) 2015-10-14
TWI546294B (zh) 2016-08-21

Similar Documents

Publication Publication Date Title
MA35576B1 (fr) Nouveaux composés
MA34650B1 (fr) Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
MA32257B1 (fr) Hydroxymethyl pyrrolidines comme agonistes des recepteurs beta-3- adrenergiques.
TN2014000420A1 (fr) Derives d'indole et d'indazole qui activent la mpk
MA43169B1 (fr) Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
EP2571876A4 (fr) Composés hétérocycliques substitués à sept chaînons en tant qu'inhibiteurs de la dipeptidyl-peptidase iv pour le traitement du diabète
MA34968B1 (fr) Urées asymétriques et utilisations médicales de celles-ci
MA41238B1 (fr) Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit
MA40219B1 (fr) Sels cristallins de (s)-6-((1-acétylpipéridin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
EA201300436A1 (ru) Совместные кристаллы и соли ингибиторов ccr3
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
CA2878796C (fr) Derives de pyridinone comme inhibiteurs de la transglutaminase tissulaire
MA35407B1 (fr) Modulateurs allostériques positifs des récepteurs nicotiniques d'acétylcholine
MA35268B1 (fr) 1-pipérazino-3-phénylindanes deutérés pour le traitement de la schizophrénie
MA44965A (fr) Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
MA32224B1 (fr) Derives de (pyrazolyl-carbonyl) imidazolidinone pour le traitement de maladies retrovirales
MA39020A1 (fr) Sels de l'acide 1 -(3-méthyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1 r)-4-(trifluorométhyl)-2,3-dihydro-lh-indén-1 -yl]-1,2,3,4-tétrahydropyrimidine-5-carboxylique
ATE525370T1 (de) Phthalazin- und pyridoä3,4- düpyridazinverbindungen als h1-rezeptor- antagonisten
EP2862573A4 (fr) Composition pour le traitement ou la prévention de maladies causées par une perméabilité vasculaire, contenant de l'imatinib ou un sel pharmaceutiquement acceptable de celui-ci en tant que principe actif
EP2543374A4 (fr) Composition pharmaceutique pour la prévention ou le traitement de l'ostéoarthrite contenant du rébamipide en tant que principe actif